Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 22Gastrointestinal 14Breast 13Thoracic 12Head & Neck 10Gynecologic 10Dermatologic 9Sarcoma 5CNS 3Plasma cell 1Other neoplasm 1NET 1Myeloid 1Endocrine 1Classical hematology 1

Conditions

Neuroendocrine Tumors 111Pheochromocytoma 33Carcinoma, Neuroendocrine 33Pituitary Neoplasms 28Thyroid Cancer, Papillary 26Paraganglioma 26Adrenocortical Carcinoma 21Neoplasms 19Gastro-enteropancreatic neuroendocrine tumor 19Thyroid Neoplasms 17Adrenal Gland Neoplasms 16Multiple Endocrine Neoplasia Type 1 14Stomach Neoplasms 13Prostatic Neoplasms 13Pancreatic Neoplasms 13Carcinoid Tumor 13Sarcoma 12Lung Neoplasms 12Breast Neoplasms 12Thyroid Carcinoma, Anaplastic 11Adenoma, Islet Cell 11Small Cell Lung Carcinoma 10Ovarian Neoplasms 10Neuroblastoma 10Neoplasm Metastasis 10Colorectal Neoplasms 10Carcinoma, Hepatocellular 10Brain Neoplasms 10Meningioma 9Esophageal Neoplasms 9

Interventions

pembrolizumab 1fludarabine 1aldesleukin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Urogenital Neoplasms × Endocrine × Clear all
NCT03412877 2026-05-29

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
285 enrolled
BreastEndocrineGynecologicNETPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Ovarian Neoplasms, Urogenital Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡